Cargando…

Outcomes with Tacrolimus-Based Immunosuppression After Kidney Transplantation from Standard- and Extended-Criteria Donors – A Post Hoc Analysis of the Prospective OSAKA Study

BACKGROUND: This post hoc analysis of data from the prospective OSAKA study evaluated the efficacy and safety of prolonged- and immediate-release tacrolimus in patients who received kidneys from extended-criteria (ECD) and standard-criteria (SCD) donors. MATERIAL/METHODS: Within the ECD and SCD grou...

Descripción completa

Detalles Bibliográficos
Autores principales: Albano, Laetitia, Banas, Bernhard, Lehner, Frank, Glyda, Maciej, Viklicky, Ondrej, Schleibner, Stefan, Brown, Malcolm, Kamar, Nassim
Formato: Online Artículo Texto
Lenguaje:English
Publicado: International Scientific Literature, Inc. 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7282531/
https://www.ncbi.nlm.nih.gov/pubmed/32467559
http://dx.doi.org/10.12659/AOT.920041
_version_ 1783544142876377088
author Albano, Laetitia
Banas, Bernhard
Lehner, Frank
Glyda, Maciej
Viklicky, Ondrej
Schleibner, Stefan
Brown, Malcolm
Kamar, Nassim
author_facet Albano, Laetitia
Banas, Bernhard
Lehner, Frank
Glyda, Maciej
Viklicky, Ondrej
Schleibner, Stefan
Brown, Malcolm
Kamar, Nassim
author_sort Albano, Laetitia
collection PubMed
description BACKGROUND: This post hoc analysis of data from the prospective OSAKA study evaluated the efficacy and safety of prolonged- and immediate-release tacrolimus in patients who received kidneys from extended-criteria (ECD) and standard-criteria (SCD) donors. MATERIAL/METHODS: Within the ECD and SCD groups, patients were randomized to one of 4 tacrolimus-based regimens (initial dose): Arm 1, immediate-release tacrolimus (0.2 mg/kg/day); Arm 2, prolonged-release tacrolimus (0.2 mg/kg/day); Arm 3, prolonged-release tacrolimus (0.3 mg/kg/day); Arm 4, prolonged-release tacrolimus (0.2 mg/kg/day) plus basiliximab. All patients received mycophenolate mofetil and bolus corticosteroids; Arms 1–3 also received tapered corticosteroids. ECDs met the definition: living/deceased donors aged ≥60 years, or 50–60 years with ≥1 other risk factor, and donation after circulatory death. Primary composite endpoint: graft loss, biopsy-confirmed acute rejection or renal dysfunction by Day 168. Outcomes were compared across treatment arms with the chi-squared or Fisher’s exact test. RESULTS: A total of 1198 patients were included in the analysis (ECD: n=620 [51.8%], SCD: n=578 [48.2%]). Patients with kidneys from ECDs were older versus SCDs (mean age, 55.7 vs. 44.5 years, p<0.0001). A higher proportion of patients with kidneys from ECDs versus SCDs met the primary composite endpoint (56.8% vs. 32.4%, p<0.0001). However, no statistically significant differences in clinical outcomes or the incidence of treatment-emergent adverse events were seen between treatment arms within each donor group. CONCLUSIONS: Worse outcomes were experienced in patients who received kidneys from ECDs versus SCDs. Prolonged-release tacrolimus provided similar graft survival to the immediate-release formulation, with a manageable tolerability profile. CLINICAL TRIAL LINK: https://clinicaltrials.gov/ct2/show/NCT00717470?term=pmr-ec-1210&draw=2&rank=1
format Online
Article
Text
id pubmed-7282531
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher International Scientific Literature, Inc.
record_format MEDLINE/PubMed
spelling pubmed-72825312020-06-19 Outcomes with Tacrolimus-Based Immunosuppression After Kidney Transplantation from Standard- and Extended-Criteria Donors – A Post Hoc Analysis of the Prospective OSAKA Study Albano, Laetitia Banas, Bernhard Lehner, Frank Glyda, Maciej Viklicky, Ondrej Schleibner, Stefan Brown, Malcolm Kamar, Nassim Ann Transplant Original Paper BACKGROUND: This post hoc analysis of data from the prospective OSAKA study evaluated the efficacy and safety of prolonged- and immediate-release tacrolimus in patients who received kidneys from extended-criteria (ECD) and standard-criteria (SCD) donors. MATERIAL/METHODS: Within the ECD and SCD groups, patients were randomized to one of 4 tacrolimus-based regimens (initial dose): Arm 1, immediate-release tacrolimus (0.2 mg/kg/day); Arm 2, prolonged-release tacrolimus (0.2 mg/kg/day); Arm 3, prolonged-release tacrolimus (0.3 mg/kg/day); Arm 4, prolonged-release tacrolimus (0.2 mg/kg/day) plus basiliximab. All patients received mycophenolate mofetil and bolus corticosteroids; Arms 1–3 also received tapered corticosteroids. ECDs met the definition: living/deceased donors aged ≥60 years, or 50–60 years with ≥1 other risk factor, and donation after circulatory death. Primary composite endpoint: graft loss, biopsy-confirmed acute rejection or renal dysfunction by Day 168. Outcomes were compared across treatment arms with the chi-squared or Fisher’s exact test. RESULTS: A total of 1198 patients were included in the analysis (ECD: n=620 [51.8%], SCD: n=578 [48.2%]). Patients with kidneys from ECDs were older versus SCDs (mean age, 55.7 vs. 44.5 years, p<0.0001). A higher proportion of patients with kidneys from ECDs versus SCDs met the primary composite endpoint (56.8% vs. 32.4%, p<0.0001). However, no statistically significant differences in clinical outcomes or the incidence of treatment-emergent adverse events were seen between treatment arms within each donor group. CONCLUSIONS: Worse outcomes were experienced in patients who received kidneys from ECDs versus SCDs. Prolonged-release tacrolimus provided similar graft survival to the immediate-release formulation, with a manageable tolerability profile. CLINICAL TRIAL LINK: https://clinicaltrials.gov/ct2/show/NCT00717470?term=pmr-ec-1210&draw=2&rank=1 International Scientific Literature, Inc. 2020-05-29 /pmc/articles/PMC7282531/ /pubmed/32467559 http://dx.doi.org/10.12659/AOT.920041 Text en © Ann Transplant, 2020 This work is licensed under Creative Common Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0 (https://creativecommons.org/licenses/by-nc-nd/4.0/) )
spellingShingle Original Paper
Albano, Laetitia
Banas, Bernhard
Lehner, Frank
Glyda, Maciej
Viklicky, Ondrej
Schleibner, Stefan
Brown, Malcolm
Kamar, Nassim
Outcomes with Tacrolimus-Based Immunosuppression After Kidney Transplantation from Standard- and Extended-Criteria Donors – A Post Hoc Analysis of the Prospective OSAKA Study
title Outcomes with Tacrolimus-Based Immunosuppression After Kidney Transplantation from Standard- and Extended-Criteria Donors – A Post Hoc Analysis of the Prospective OSAKA Study
title_full Outcomes with Tacrolimus-Based Immunosuppression After Kidney Transplantation from Standard- and Extended-Criteria Donors – A Post Hoc Analysis of the Prospective OSAKA Study
title_fullStr Outcomes with Tacrolimus-Based Immunosuppression After Kidney Transplantation from Standard- and Extended-Criteria Donors – A Post Hoc Analysis of the Prospective OSAKA Study
title_full_unstemmed Outcomes with Tacrolimus-Based Immunosuppression After Kidney Transplantation from Standard- and Extended-Criteria Donors – A Post Hoc Analysis of the Prospective OSAKA Study
title_short Outcomes with Tacrolimus-Based Immunosuppression After Kidney Transplantation from Standard- and Extended-Criteria Donors – A Post Hoc Analysis of the Prospective OSAKA Study
title_sort outcomes with tacrolimus-based immunosuppression after kidney transplantation from standard- and extended-criteria donors – a post hoc analysis of the prospective osaka study
topic Original Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7282531/
https://www.ncbi.nlm.nih.gov/pubmed/32467559
http://dx.doi.org/10.12659/AOT.920041
work_keys_str_mv AT albanolaetitia outcomeswithtacrolimusbasedimmunosuppressionafterkidneytransplantationfromstandardandextendedcriteriadonorsaposthocanalysisoftheprospectiveosakastudy
AT banasbernhard outcomeswithtacrolimusbasedimmunosuppressionafterkidneytransplantationfromstandardandextendedcriteriadonorsaposthocanalysisoftheprospectiveosakastudy
AT lehnerfrank outcomeswithtacrolimusbasedimmunosuppressionafterkidneytransplantationfromstandardandextendedcriteriadonorsaposthocanalysisoftheprospectiveosakastudy
AT glydamaciej outcomeswithtacrolimusbasedimmunosuppressionafterkidneytransplantationfromstandardandextendedcriteriadonorsaposthocanalysisoftheprospectiveosakastudy
AT viklickyondrej outcomeswithtacrolimusbasedimmunosuppressionafterkidneytransplantationfromstandardandextendedcriteriadonorsaposthocanalysisoftheprospectiveosakastudy
AT schleibnerstefan outcomeswithtacrolimusbasedimmunosuppressionafterkidneytransplantationfromstandardandextendedcriteriadonorsaposthocanalysisoftheprospectiveosakastudy
AT brownmalcolm outcomeswithtacrolimusbasedimmunosuppressionafterkidneytransplantationfromstandardandextendedcriteriadonorsaposthocanalysisoftheprospectiveosakastudy
AT kamarnassim outcomeswithtacrolimusbasedimmunosuppressionafterkidneytransplantationfromstandardandextendedcriteriadonorsaposthocanalysisoftheprospectiveosakastudy